Abstract: Carboplatin is a second-generation platinum-based chemotherapeutic agent developed to mitigate the severe systemic toxicities associated with its predecessor, cisplatin. By forming DNA crosslinks that induce double-strand breaks, carboplatin triggers the DNA damage response and subsequent apoptosis, particularly in tumors with homologous recombination deficiencies. While it has become a cornerstone in the treatment of various malignancies—including ovarian, lung, breast, and urothelial cancers—transient responses and the emergence of drug resistance remain significant clinical challenges. Recently, the research direction has heavily shifted toward chemo-immunotherapy combinations. Carboplatin not only exerts direct cytotoxic effects but also modulates the tumor microenvironment by promoting neoantigen release, depleting immunosuppressive regulatory T-cells, and enhancing T-cell infiltration. This literature review synthesizes current evidence on carboplatin, focusing on its pharmacological activity, molecular mechanisms, structure-activity relationships, current limitations, and its evolving role in synergistic combinations with immune checkpoint inhibitors.
1. Introduction
Cisplatin, the first-generation platinum-based anti-cancer drug, was approved in 1978 and demonstrated significant efficacy against various malignant tumors. However, its long-term use was severely limited by non-specific systemic toxicities that caused serious damage to normal tissues [9]. To address these safety concerns, carboplatin was developed as a second-generation platinum chemotherapy drug and reached the clinic in the 1980s [9]. Carboplatin exhibits a much higher biosafety profile, allowing it to be administered at higher doses for aggressive tumors [9].
Today, carboplatin is a standard-of-care backbone in the treatment of numerous cancers, including small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), ovarian cancer, and urothelial carcinoma [1] [3] [4] [5]. Despite its widespread use, chemotherapy alone often yields transient responses, and patients frequently relapse with platinum-resistant disease [1] [3]. Consequently, modern oncological research has pivoted toward combining carboplatin with immunotherapy. The integration of programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors with carboplatin-based regimens has created a paradigm shift, offering durable responses and establishing new standards of care across multiple oncology indications [1] [2].
2. Pharmacological Activity
Carboplatin functions primarily as a cytotoxic agent, but its pharmacological activity extends significantly into immunomodulation, providing a strong rationale for chemo-immunotherapy combinations. Cytotoxic chemotherapy induces cancer cell death, which leads to the release of neoantigens that facilitate antigen presentation and tumor recognition by the immune system [1]. Furthermore, carboplatin can deplete the tumor microenvironment of immunosuppressive myeloid-derived cells and regulatory T-cells, thereby promoting intratumoral T-cell infiltration and activation [1].
Clinically, carboplatin is frequently combined with other cytotoxic agents (such as paclitaxel, etoposide, or gemcitabine) and immune checkpoint inhibitors. In extensive-stage SCLC, the addition of the PD-L1 inhibitors atezolizumab or durvalumab to carboplatin and etoposide significantly improved overall survival (OS) and progression-free survival (PFS), establishing new first-line standards of care [1]. In NSCLC, the KEYNOTE-021 study demonstrated that combining pembrolizumab with carboplatin and pemetrexed significantly improved objective response rates compared to chemotherapy alone [2]. In early-stage TNBC, the KEYNOTE-522 trial showed that adding pembrolizumab to a carboplatin/paclitaxel backbone substantially increased pathological complete response (pCR) rates [5]. In advanced urothelial carcinoma, carboplatin plus gemcitabine is the standard for cisplatin-ineligible patients, and recent protocols utilize avelumab as a first-line switch-maintenance therapy for patients who do not progress on this initial chemotherapy [4] [8]. Carboplatin is also being explored in neoadjuvant chemo-immunotherapy settings for resectable esophageal cancer [11].
Pharmacokinetically, carboplatin dosing is highly dependent on renal function. Clearance is primarily determined by the glomerular filtration rate (GFR). Dosing algorithms, most notably the Calvert formula, utilize the patient's GFR to target a specific area under the concentration-time curve (AUC), ensuring optimal exposure while minimizing toxicity [6] [10].
3. Molecular Mechanism of Action
The efficacy of carboplatin is regulated by its intracellular and intra-nuclear accumulation, which is balanced by influx transporters (such as copper and solute carrier transporters) and efflux pumps (like multi-drug resistance protein-1) [3]. Once inside the nucleus, carboplatin modifies DNA and RNA through covalent linkages. It binds covalently to the N-7 position of guanine, forming monoadducts that subsequently develop into intra-strand or inter-strand crosslinks [3].
These structural distortions in the DNA double helix activate the DNA damage response (DDR) network. The DDR halts DNA replication and transcription, inducing cell cycle arrest to allow the cell time to repair the lesions. If the damage is too severe to be repaired, the cell undergoes apoptosis or mitotic catastrophe [3]. Tumors with defective DNA repair mechanisms, particularly those with homologous recombination deficiency (HRD) such as BRCA1 or BRCA2 mutations, exhibit a "BRCAness" phenotype and are highly sensitive to carboplatin-induced double-strand breaks [3] [5].
4. Structure-Activity Relationship (SAR)
Carboplatin was rationally designed to overcome the severe toxicities of cisplatin. Structurally, carboplatin replaces the two chloride leaving groups of cisplatin with a bidentate cyclobutane dicarboxylic acid ligand [9]. This specific structural modification results in a significantly lower hydration rate and slower reaction kinetics compared to the highly reactive cisplatin [3] [9].
Because the cyclobutane dicarboxylic acid ligand is more stable and leaves the platinum complex much more slowly, carboplatin exhibits high biosafety and greatly reduced systemic toxicities. Specifically, it causes substantially less hepatotoxicity, nephrotoxicity, neurotoxicity, and ototoxicity than cisplatin [9]. This favorable toxicity profile is what allows carboplatin to be administered safely at higher doses and makes it an ideal backbone for combination therapies, including those with immunomodulatory agents [1] [9].
5. Current Limitations
Despite its advantages over cisplatin, carboplatin therapy faces several critical limitations:
Toxicity: While non-hematological toxicities are reduced, carboplatin is associated with significant dose-limiting hematological adverse events. Grade 3-4 toxicities such as anemia, neutropenia, and thrombocytopenia are common, particularly when combined with other cytotoxic agents or immunotherapies [1] [5] [13].
Drug Resistance: Both primary and acquired platinum resistance remain major hurdles. Resistance mechanisms are complex and multifactorial, including: (1) decreased intra-nuclear drug levels due to altered influx/efflux transporters or deactivation by glutathione; (2) enhanced DNA repair and tolerance, often through secondary reversion mutations in BRCA1/2 that restore homologous recombination function, or loss of 53BP1; (3) alterations in cell survival pathways (e.g., STAT3, BCL2); and (4) changes in the tumor microenvironment [3] [7].
Immunosuppressive Microenvironments: In certain cancers like high-grade serous ovarian cancer (HGSOC), the immune tumor microenvironment (iTME) is highly immunosuppressive. This "immune privilege" can prevent adaptive immune responses and override the clinical benefits of immune checkpoint blockade, limiting the efficacy of chemo-immunotherapy combinations in these specific patient populations [3].
6. Future Perspectives
The future of carboplatin-based therapy lies in optimizing its use within combination regimens and overcoming resistance mechanisms. A major priority is the identification of robust predictive biomarkers. Currently, markers like PD-L1 expression and tumor mutational burden (TMB) have shown inconsistent predictive utility for chemo-immunotherapy efficacy in diseases like SCLC, necessitating the discovery of novel multimodal biomarkers [1].
Advancements in multiparameter single-cell proteomic technologies, such as mass cytometry (CyTOF) and multiplex cellular imaging, are providing unprecedented insights into the tumor microenvironment. By mapping the spatial arrangements and phenotypic states of immune cells (e.g., exhausted T-cells, macrophages, and NK cells) on a cell-by-cell basis, researchers aim to unravel the complex interplay between carboplatin-induced DNA damage and immune activation. This could identify new druggable targets to reverse immunosuppression and platinum resistance [3].
Furthermore, novel therapeutic combinations continue to be explored. Carboplatin is being tested alongside PARP inhibitors to exploit synthetic lethality in HRD tumors, as well as with targeted agents like the mTORC1/2 inhibitor sapanisertib, which has shown preclinical potential to restore sensitivity to platinum chemotherapy [3] [13]. Additionally, combinations with oncolytic viruses (e.g., reovirus) are being evaluated in early-phase trials to further stimulate anti-tumor immune responses [12]. These rational, model-informed combinations hold the promise of transforming transient chemotherapy responses into durable, long-term survival for patients with advanced malignancies.
